Spiden

Spiden is a Swiss biomedical monitoring company based in Pfäffikon, Switzerland. It is engaged in the development of non-invasive, needle-free sensing technology intended to provide continuous insight into human biochemistry. The company's public-facing consumer proposition is marketed under the LIOM brand, described as "the ultimate health wearable for conscious living." According to the LIOM website, the platform is designed to offer a continuous, needle-free window into the body's chemistry, beginning with glucose measurement. The core technological claim is that LIOM can perform precision biomarker measurements without piercing the skin, which the company describes as a world first. The website states that continuous measurements were achieved over six hours on a study subject, with comparison against invasive reference data. This positions Spiden in the emerging category of metabolic and biochemical wearables, distinct from conventional activity trackers that measure movement, heart rate, and sleep but not blood chemistry. Spiden's LIOM platform is presented as combining multiple signal streams in real time to generate health insights across several domains: metabolic monitoring (continuous biomarker tracking, predictive alerts, meal optimization, time-in-range, metabolic responsiveness), fitness (metabolic burn, activity tracking, heart rate zones), cardiovascular monitoring (heart rate, resting and non-resting heart rate, variability, respiratory rate, cardiovascular flexibility), sleep (quality analysis, duration and stages, wind-down and wake-up, metabolic interrupters), and mental performance (focus and energy, mental balance, stress factors, metabolic contributors). The company has announced a public event, LIOM Day 2026, scheduled for November 5 in Pfäffikon, where it plans to publicly demonstrate its miniaturized sensing technology for the first time and share progress toward bringing the needle-free health wearable closer to reality. A waitlist is available for interested users. Spiden operates as a private company. Its corporate identity is tied to the LIOM consumer brand, and the website references "Liom Health AG" as the entity holding data on file. The company's focus on glucose as the first biomarker reflects a strategic view that small irregularities in glucose metabolism compound over time and that awareness is a powerful tool for prevention.

Spiden is a Swiss biomedical monitoring company headquartered in Pfäffikon, Switzerland. Public information about the company is limited, but its corporate identity is closely tied to the development of non-invasive biochemical sensing technology and to its consumer-facing LIOM brand. The company's central technological pursuit is a needle-free method for continuously measuring biomarkers in the body. According to the LIOM website, the platform provides "a continuous, needle-free window into your body's chemistry, starting with glucose." The company claims that its technology enables "precision biomarker measurements without piercing the skin," which it describes as a world first, and states that continuous measurements were achieved over six hours on a study subject, with comparison to invasive reference data. Spiden's strategic rationale for beginning with glucose is explained on the LIOM site: "Small irregularities in glucose metabolism compound over time. The progression from healthy to disease is often imperceptible. Awareness is a powerful tool for prevention." This positions the company in the preventive health and metabolic monitoring space. The LIOM platform is presented as integrating multiple real-time signals to deliver insights across metabolic, fitness, cardiovascular, sleep, and mental performance domains. This multi-domain approach distinguishes it from single-purpose continuous glucose monitors and from conventional wearables that do not measure blood chemistry. Spiden has announced a public event, LIOM Day 2026, to be held on November 5 in Pfäffikon. At this event, the company plans to publicly demonstrate its miniaturized sensing technology for the first time and to share progress toward commercializing the LIOM wearable. A waitlist has been opened for interested users. The company operates as a private entity. The LIOM website references "Liom Health AG" as the organization holding data on file, indicating a corporate structure in which Spiden and Liom Health AG are related. No founding date, founder names, funding details, or executive leadership have been disclosed in the available evidence.

• LIOM Day 2026 scheduled in Pfäffikon for first public demonstration of miniaturized sensing technology.

Developer of non-invasive, needle-free continuous biochemical sensing for consumer health wearables, starting with glucose monitoring.

• LIOM health wearable

  A needle-free continuous health wearable that measures biochemistry, starting with glucose, and combines metabolic, fitness, cardiovascular, sleep, and mental performance signals.

1. 1LIOM - The Ultimate Health Wearableliom.com
2. 2Spiden - Wikidatawikidata.org